Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT

Innovative mental health medicines for patients with unmet needs

The Unmet Need

2 out of 3

people prescribed antidepressants are women[1] 

There's a story behind each one of the numbers...

11,109,000

people received a mental health prescription in the UK during 2021[1] 

"I’m very hopeful that in the months to come KRN-101 will be the start of something amazing"

Chief Medical Oficer
Dr Malcolm Barratt-Johnson

A patient-first approach

Albert Labs is a pharmaceutical company focused on natural neurological therapies to treat the immediate, unmet needs of the ever-worsening mental health crisis.

Our Clinical Trials

Industry News

discrimination in mental health
  • October 22, 2022
  • The Lancet

The Lancet Commission on Ending Stigma and Discrimination in Mental Health

Prof Graham Thornicroft PhD, Charlene Sunkel NSC, et al.

Industry News

Innovation Passport
  • October 12, 2022
  • PSYCH

The MHRA’s Innovation Passport

Industry News

pharmaceutical dependence
  • October 12, 2022
  • Vogue

Can Psilocybin Challenge Our Pharmaceutical Dependence?

Fiorella Valdesolo

Industry News

anxiety distress cancer
  • September 27, 2022
  • The Economist

Psychedelic Therapy could reduce Anxiety, Distress among Patients with Cancer

Alok Jha

Industry News

Alcohol Use Disorder psilocybin
  • August 24, 2022
  • Jama Network

Psilocybin-Assisted Psychotherapy Treatment with Alcohol Use Disorder: A Randomized Clinical Trial

Michael P. Bogenschutz, MD; Stephen Ross, MD; Snehal Bhatt, MD; et al

Previous
Next

A breakthrough for mental health

Studies have displayed psilocybin as a breakthrough for mental health care. Read about our natural psilocybin medicine: KRN-101.[2]

Our Technology

Rethinking the clinical trial paradigm

Traditional clinical trial infrastructure means people currently suffering could be waiting 5 or more years for psilocybin therapy to be available to them.

Albert Labs is strategically placed in the UK, where innovative licensing and access programs are available. These programs also provide a pathway to the rest of the world.

UK clinical focus, supported by our Canadian and Portuguese research & development laboratories.

It is our promise to deliver our innovative mental health medicine to patients with urgent and unmet needs.

Our Clinical Trials

“Albert Labs’ first target product, KRN-101, is a potential solution for cancer-related anxiety, which affects over 15 million people across the world.”

Dr. Michael Raymont, CEO

Faster

Faster

Real-World Evidence can accelerate innovation and access for patients currently suffering from unmet needs. A clinical pathway previously used for Covid-19 vaccines and cancer treatments in the UK.

Scalabe

Scalable

Leveraging existing clinic & research infrastructure and preidenitfied, accessible patient pools, through collaboration with established hospital networks.

Credible

Credible

Strategically placed in the UK to make use of the Real-World Evidence protocol, which provides crucial data and insights for licensing & regulation of prescribed medicine.

Focu

Focused

Patient-centric data and early clinician engagement will build and deliver these breakthroughs safely and effectively to those most in need.

For the patients suffering most

Tens of millions of people are diagnosed with cancer each year, and millions more are living with it. The depression and anxiety that might accompany cancer is self-evident, more commonly known as cancer distress.

Worry, sleeplessness, fear, and doubts regarding the meaning of one’s life are commonplace with a cancer diagnosis.

Due to the complexities surrounding cancer therapy, too often, patients’ psychological needs are left untreated.

Albert Labs’ first target product, KRN-101, is a potential solution for cancer-related distress.

Our Clinical Trials
0

people receive a mental health prescription in the UK[3] 

0

patients live with a mental health disorder worldwide[4] 

0

patients suffer from cancer related distress in the UK[5] 

0

patients suffer from cancer related distress worldwide[6] 

Meet our team

Everyone has been impacted by mental health and our expert team is no exception. We know the immense struggle and we endeavour to find better solutions for all.

Our people bring experience and expertise across multiple fields to deliver a scalable solution to the mental health crisis.

Our Team

Mike Thompson MBE

Non-Executive Director

“The life sciences industry are well aware of the significant gap that still remains in alleviating related mental health distress”[7] 

Professor Joanna Neill

Chair, Clinical Advisory Board

“Psychedelic therapy heals people. Thats really not something I’ve seen us do in psychiatry in all my career”[8]

Professor Sara Tai

Principal Investigator

“I value Albert Labs’ emphasis on ethical and patient-centred investigations of the effectiveness of psychotherapy and psilocybin. ”[9]

Dr Malcolm Barratt-Johnson

Chief Medical Officer

“It is an extremely exciting time for Albert Labs, we’re looking forward to treating our first patients with our product.”[10]

The history

PSILOCYBIN

sil-uh-sahy-bin

Psilocybin is a naturally occuring tryptamine alkaloid found in over 200 species of fungi. It is a serotonin 2A receptor agonist, which after a single dose can have long-lasting beneficial effects on mood, personality, and potentially on mindfulness. Imagery found on prehistoric murals suggests that human usage of psilocybin mushrooms predates recorded history.

1200px Psilocybn.svg

1958

Sandoz Laboratory Basel, Switzerland

Albert Hofmann, a Swiss chemist, pioneered the development & isolation of psilocybin. Understanding its therapeutic value first-hand. [11] 

Sandoz 1

1960

Sandoz introduced Indocybin™

Marketed by Sandoz as Indocybin™ for psychopharmacological and therapeutic clinical research. [12] 

Indocybin 1

1971

United Nations Treaty - Convention on psychotropic substances

Set up to control psychoactive drugs such as amphetamine-type stimulants, barbiturates, benzodiazepines, and psychedelics. Despite psilocybin’s utility as a medical therapy it was scheduled in the highest class, resulting in the discontinuation of medical research. [13] 
UN Treaty 1

35 Years later

2006

Moreno et al, at the University of Arizona

The team concluded that in a controlled clinical environment, psilocybin was safely used in 9 subjects with Obsessive Compulsive Disorder (OCD) and was associated with acute reductions in cores symptoms.[14] 

2012

R Carhart-Harris et al, at Imperial College London

ICL Psilocybin 3
30 healthy volunteers had psilocybin infused into their blood while inside magnetic resonance imaging (MRI) scanners, which measure changes in brain activity. The effects need to be investigated further but we must be interested in exploring psilocybin’s therapeutic potential. [16] 

2016

R Griffiths et al, at Johns Hopkins School of Medicine

The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. High-dose psilocybin produced large decreases in measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. [17] 

2011

C Grob et al, at UCLA School of Medicine

Dr Grob investigated the clinical application of psilocybin in the treatment of anxiety reactive to advanced-stage cancer. In a double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, the active group showed clear mood improvements compared to the control. [15] 

2016

S Ross et al, at NYU School of Medicine

29 patients with cancer-related anxiety and depression were dosed with psilocybin or active-placebo, both in conjunction with psychotherapy. psilocybin arm produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness. At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety. [18] 

Studies have displayed psilocybin as a breakthrough for mental health care [2] 

Albert Labs’ first target product, KRN-101, is a potential solution for cancer-related anxiety, which affects over 15 million people across the world.

Our Clinical Trials
White Logo

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2022 Albert Labs. All Rights Reserved

Hear more from our team

Our people bring experience and expertise across multiple fields to deliver a scalable solution to the mental health crisis.

  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact investing@albertlabs.com

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

Twitter
Youtube
Linkedin
Instagram
Envelope

Latest Press Release

Albert Labs Announces Private Placement

Read more
Twitter
Youtube
Linkedin
Instagram
Envelope

Latest Press Release

Albert Labs Announces Private Placement

Read more

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok